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Hepatocellular carcinoma (HCC) is the fifth most commonly diagnosed cancer and the second most common cause of cancer-
related death worldwide. Sorafenib (Sora) is used as a targeted therapy for HCC treatment. Mesenchymal stem cells (MSCs) are
applied as a new approach to fight malignancies. Drug resistance and side effects are the major concerns with Sora administration.
(e effect of using the combination of sorafenib and MSCs on tumor regression in xenograft HCC models was evaluated in this
study.Methods and Materials. Human hepatocellular carcinoma cell lines (HepG2) were subcutaneously implanted into the flank
of 18 nude mice.(e animals were randomly divided into six groups (n� 3); each received Sora (oral), MSCs (IV injection), MSCs
(local injection), Sora +MSCs (IV injection), Sora +MSCs (local injection), or no treatment (the control group). Six weeks after
tumor implantation, the mice were scarified and tumoral tissues were resected in their entirety. Histopathological and im-
munohistochemical evaluations were used tomeasure tumor proliferation and angiogenesis. Apoptotic cells were quantified using
the TUNEL assay. Results. No significant difference was found in the tumor grade among the treatment groups. Differentiation
features of the tumoral cells were histopathologically insignificant in all the groups. Tumor necrosis was highest in the hpMSC
(local) + Sora group. Tumor cell proliferation was reduced in hpMSC (local) + Sora-treated and hpMSC (IV) + Sora-treated mice
compared with the other groups. Apoptotic-positive cells occupied a greater proportion in the Sora, hpMSC (IV) + Sora, and
hpMSC (local) + Sora groups. Conclusion. A combination of chemotherapy and MSC can yield to more favorable results in the
treatment of HCC.
1. Introduction
HCC is the fifth most common malignant tumor and
contributes to about 800,000 deaths globally per annum
[1–3]. Only a small fraction of patients with HCC are
candidates for curative treatments, such as surgical
resection, liver transplantation, or radiofrequency ablation
[4]. Although numerous novel strategies have been proposed
to treat HCC [5], including cell-based therapies, the disease
remains challenging to combat.
Sorafenib is the only FDA-approved drug that is ad-
ministered as the first line systemic therapy in advanced
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